Fda advisory committee recommends use of investigational drug maribavir (tak-620) to treat post-transplant recipients with cytomegalovirus (cmv) infection and disease refractory to treatment with or without resistance

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the u.s. food and drug administration (fda) antimicrobial drugs advisory committee (amdac) voted unanimously to recommend use of maribavir (tak-620) for the treatment of refractory cytomegalovirus (cmv) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. the committee also voted unanimo
TAK Ratings Summary
TAK Quant Ranking